Literature DB >> 28249900

LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases.

Guilin Qiao1, Jianzhong Qin1, Nicholas Kunda1, Jed F Calata1, Dolores L Mahmud2, Peter Gann3, Yang-Xin Fu4, Steven A Rosenberg5, Bellur S Prabhakar6, Ajay V Maker7,6.   

Abstract

The majority of patients with colon cancer will develop advanced disease, with the liver being the most common site of metastatic disease. Patients with increased numbers of tumor-infiltrating lymphocytes in primary colon tumors and liver metastases have improved outcomes. However, the molecular factors that could empower antitumor immune responses in this setting remain to be elucidated. We reported that the immunostimulatory cytokine LIGHT (TNFSF14) in the microenvironment of colon cancer metastases associates with improved patient survival, and here we demonstrate in an immunocompetent murine model that colon tumors expressing LIGHT stimulate lymphocyte proliferation and tumor cell-specific antitumor immune responses. In this model, increasing LIGHT expression in the microenvironment of either primary tumors or liver metastases triggered regression of established tumors and slowed the growth of liver metastases, driven by cytotoxic T-lymphocyte-mediated antitumor immunity. These responses corresponded with significant increases in tumor-infiltrating lymphocytes and increased expression of lymphocyte-homing signals in the metastatic tumors. Furthermore, we demonstrated evidence of durable tumor-specific antitumor immunity. In conclusion, increasing LIGHT expression increased T-cell proliferation, activation, and infiltration, resulting in enhanced tumor-specific immune-mediated tumor regressions in primary tumors and colorectal liver metastases. Mechanisms to increase LIGHT in the colon cancer microenvironment warrant further investigation and hold promise as an immunotherapeutic strategy. Cancer Res; 77(8); 1880-91. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28249900      PMCID: PMC5410174          DOI: 10.1158/0008-5472.CAN-16-1655

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response.

Authors:  K Tamada; K Shimozaki; A I Chapoval; Y Zhai; J Su; S F Chen; S L Hsieh; S Nagata; J Ni; L Chen
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

4.  Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.

Authors:  Ajay V Maker; Giao Q Phan; Peter Attia; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Leah R Haworth; Catherine Levy; David Kleiner; Sharon A Mavroukakis; Michael Yellin; Steven A Rosenberg
Journal:  Ann Surg Oncol       Date:  2005-10-21       Impact factor: 5.344

5.  T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

Authors:  Maria R Parkhurst; James C Yang; Russell C Langan; Mark E Dudley; Debbie-Ann N Nathan; Steven A Feldman; Jeremy L Davis; Richard A Morgan; Maria J Merino; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Giao Q Phan; Ramona M Lim; Stephen A Wank; Nicholas P Restifo; Paul F Robbins; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

6.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

7.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  12 in total

Review 1.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

2.  Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.

Authors:  Manuel F Fernandez; Guilin Qiao; Kiara Tulla; Bellur S Prabhakar; Ajay V Maker
Journal:  J Surg Res       Date:  2021-02-22       Impact factor: 2.417

3.  TNFSF14/LIGHT, a Non-Canonical NF-κB Stimulus, Induces the HIF Pathway.

Authors:  Laura D'Ignazio; Michael Batie; Sonia Rocha
Journal:  Cells       Date:  2018-08-08       Impact factor: 6.600

4.  Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells.

Authors:  Xiu-Man Zhou; Wan-Qiong Li; Ya-Hong Wu; Lu Han; Xin-Guang Cao; Xuan-Ming Yang; Hong-Fei Wang; Wen-Shan Zhao; Wen-Jie Zhai; Yuan-Ming Qi; Yan-Feng Gao
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

5.  Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells.

Authors:  Marjolein Schluck; Roel Hammink; Carl G Figdor; Martijn Verdoes; Jorieke Weiden
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 6.  TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy.

Authors:  Joseph G Skeate; Mikk E Otsmaa; Ruben Prins; Daniel J Fernandez; Diane M Da Silva; W Martin Kast
Journal:  Front Immunol       Date:  2020-05-15       Impact factor: 7.561

7.  Prognostic Value of SLC4A4 and its Correlation with Immune Infiltration in Colon Adenocarcinoma.

Authors:  Xiaoli Chen; Jianing Chen; Yan Feng; Wei Guan
Journal:  Med Sci Monit       Date:  2020-09-19

8.  Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.

Authors:  Marco Stringhini; Jacqueline Mock; Vanessa Fontana; Patrizia Murer; Dario Neri
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

9.  Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.

Authors:  Guozhu Xie; Tan Cheng; Jie Lin; Lanfang Zhang; Jieling Zheng; Ying Liu; Guobo Xie; Baiyao Wang; Yawei Yuan
Journal:  J Immunother Cancer       Date:  2018-09-12       Impact factor: 13.751

10.  Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.

Authors:  Shiyun Dai; Yun Lv; Weidong Xu; Yuefeng Yang; Chao Liu; Xiwen Dong; Huan Zhang; Bellur S Prabhakar; Ajay V Maker; Prem Seth; Hua Wang
Journal:  Cancer Gene Ther       Date:  2020-04-20       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.